July 25, 2016: Here are four stocks trading with heavy volume among 18 equities making new 52-week lows in Monday’s session. NYSE decliners led advancers by about 2 to 1 and Nasdaq decliners led advancers by about 5 to 4.
Skechers U.S.A. Inc. (NYSE: SKX) lost nearly 3.6% Monday to post a new 52-week low of $24.10 versus a high of $54.53 after closing Friday at $24.99. Volume totaled nearly 8 million shares, more than double the daily average of nearly 3 million shares. The sneaker company had no specific news Monday.
Tobira Therapeutics Inc. (NASDAQ: TBRA) dropped about 61% on Monday to post a new 52-week low of $4.40 against a 52-week high of $15.63. Volume of around 3 million was nearly 30 times the daily average of around 80,000. The stock closed at $11.25 on Friday night. The company reported that a phase IIb trial of a liver disease treatment failed to meet its primary endpoint.
Cameco Corp. (NYSE: CCJ) slipped 1.9% on Monday to post a new 52-week low of $10.15 after closing at $10.35 on Friday. The stock’s 52-week high is $14.79. Volume was 35% below the daily average of around 1.6 million shares. The Canada-based miner had no specific news, but low uranium prices continue to plague the company.
Ziopharm Oncology Inc. (NASDAQ: ZIOP) fell by around 1% on Monday to post a new 52-week low of $4.45 against a high of $14.93. The stock closed at $4.49 on Friday night. Volume was less than half the stock’s daily average of around 2.6 million. The company had no specific news Monday.
Want to Retire Early? Start Here (Sponsor)
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
